Initial evidence for the therapeutic potential of BET inhibitors in cancer was observed in models of NUT midline carcinoma (NMC) [12], a rare but lethal malignancy characterized by chromosomal translocations that express a fusion protein encoded by the bromodomains of BRD4 (or less frequently, BRD3) and the NUT locus [15]. Here, BRD4 is linked to nut midline carcinoma.